BioSpace News Archive

NurExone Biologic Inc., a pioneering biopharmaceutical company, finalized a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology.

Akero Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA, is pleased to provide the following corporate updates.

Ainos, Inc. (NASDAQ:AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the year ended December 31, 2023.

As we age, our hematopoietic stem cells become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that it will share data across its dermatologic portfolio of gene expression profile (GEP) tests via oral and electronic poster presentations at the 2024 AAD Annual Meeting, taking place March 8-12 in San Diego.

Graphite Bio, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics, Inc. pursuant to the Agreement and Plan of Merger, dated November 14, 2023.

DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at Barclays Global Healthcare Conference 2024 on Wednesday, March 13, 2024, at 8:00 a.m. EDT.